Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
2021 · Annals of Surgical Oncology · 64 citations
https://doi.org/10.1245/s10434-021-10991-2
J
Jennifer A. Yonkus
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
131
Papers
630
Citations
13
h-index
17
i10-index
Jennifer A. Yonkus is an academic researcher from Mayo Clinic in Arizona. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics & Neuroendocrine Tumor Research Advances. The author has an h-index of 13, co-authored 112 publications.
ORCID: 0000-0001-9915-6184Papers by this author
worksFDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
2022 · Journal of the National Comprehensive Cancer Network · 54 citations
https://doi.org/10.6004/jnccn.2022.7041
In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
2023 · Communications Biology · 4 citations
https://doi.org/10.1038/s42003-023-05368-y
Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study
2025 · Annals of Surgical Oncology · 3 citations
https://doi.org/10.1245/s10434-025-17036-y
Data from Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma
2024 · 0 citations
https://doi.org/10.1158/1541-7786.c.6706645.v3
Supplementary Figure S1 from Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma
2024 · 0 citations
https://doi.org/10.1158/1541-7786.27034981
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat